Diabetic kidney disease affects a growing proportion of people with diabetes and remains the leading cause of end-stage renal ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...